<img alt="" src="https://secure.soil5hear.com/223550.png" style="display:none;">

Autologous AML Platform

Champions Oncology's ex vivo AML co-culture platform for Immuno-Oncology therapeutic testing 


Champions Oncology has launched an innovative new platform enabling Acute Myeloid Leukemia (AML) researchers the ability to better understand their therapeutic mechanism of action.  The Autologous AML Platform is an ex vivo co-culture assay developed and optimized to interrogate the responses of your immuno-oncology drugs in only 4 days using primary patient specimens.  

Download to learn more about the Autologous AML Platform.

Auto AML Fact Sheet Panel_Landing Page_809x423 copy